MIA3

Across TCGA pan-cancer cohorts, MIA3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MIA3 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MIA3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MIA3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where MIA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.810	0.461	.014	10	view →
LSCC	DFS	Median	All	0.718	0.871	.025	3	view →
HNSC	DFS	Tertile	III,IV	0.916	1.000	.038	1	view →
LUAD	DFS	Median	All	0.898	1.000	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MIA3–PDAC (DFS)

Open the PDAC breakdown →